EURECA Study Achieves First 1000 Patients!

The EURECA study reached the first thousand of cases, at only one week apart from ASPIRE-ICU’s own first 1000 inclusions! This means over the 50% of global estimation has been included in the EURECA study, including 40% of total CRE estimation and 85% of total CRAB estimation.

With regards to the case/control studies more than half required “matched packs” are matched. The team will work hard on this aspect of the study to achieve the total amount as soon as possible.

The period of recruitment is until the end of February 2018. Recruitment is competitive so all sites are on time to include as many patients as possible. Thanks to the efforts and commitment of all activated sites the inclusion rate has been excellent during summertime, thus the study is well on its way to achieve the objectives on time!

The top enrolling sites in the study are:

1. Clinical Center of Serbia (Dr. Biljana Carevic), Serbia: 131 patients
2. Hospital Universitario Reina Sofia (Dr. Julian De la Torre Cisneros), Spain: 118 patients Hospital Universitario Carlos Haya (Dr. Juan de Dios Colmenero), Spain: 113 patients
3. Hospital Universitari de Bellvitge (Dr. Evelyn Shaw), Spain: 75 patients
4. Laiko General Hospital (Dr. George D. Laikos), Greece: 74 patients

The communication and collaboration between all COMBACTE collaborators, partners, national coordinators, and research teams keeps on being excellent. This proves the enormous value of the COMBACTE network, and the reality that through it any objectives set forth can be achieved. The information provided by the study is interesting not only for the scientific community, but also for the global community.

EURECA is a prospective observational study on cohorts of patients with serious carbapenem-resistant Gram-negative bacterial infections. It aims to learn how patients across Europe are infected and currently treated. And which subgroups of patients respond well to which treatments.